LOGIN MBS303

mbs303MBS 303 is a bispecific antibody targeting CD3CD20 being developed by Beijing Mabworks Biotech for the treatment of B cell non-Hodgkin lymphoma. TheMBS303, composed of a 2:1 bispecific antibody structure, binds to CD20 with two arms and CD3 molecule with one arm to increase affinity with tumor cells and decrease the off-target toxicity